(Total Views: 703)
Posted On: 04/03/2021 10:20:47 AM
Post# of 148887
Can someone please explain why anyone would expect an EUA for a patient population that you then subsequently need to recruit patients for a Phase 3 trial?
A lot of fellow longs seem to have suspended their ability to think logically because of what they WANT to have happen.
If Cytodyn management was discussing CD16 as a Phase 4 trial, then an EUA would still be possible. As it stands now, I think it's far less likely than is being hoped for.
I also believe that management has been very selective in the CD12 data they have released. I can only think that they do not want to release the data in its entirety because they are trying to present it in the most favorable light possible.
If you don't agree, look at the 'rope-a-dope' they've been giving us shareholders about the HIV BLA. That's been years in the making and we still haven't been told how they plan on providing receptor occupancy tests AFTER THE FACT. It's what we're not being told that should concern us.
Long on Leronlimab, short on patience for 'management'.
A lot of fellow longs seem to have suspended their ability to think logically because of what they WANT to have happen.
If Cytodyn management was discussing CD16 as a Phase 4 trial, then an EUA would still be possible. As it stands now, I think it's far less likely than is being hoped for.
I also believe that management has been very selective in the CD12 data they have released. I can only think that they do not want to release the data in its entirety because they are trying to present it in the most favorable light possible.
If you don't agree, look at the 'rope-a-dope' they've been giving us shareholders about the HIV BLA. That's been years in the making and we still haven't been told how they plan on providing receptor occupancy tests AFTER THE FACT. It's what we're not being told that should concern us.
Long on Leronlimab, short on patience for 'management'.
(13)
(3)Scroll down for more posts ▼
